The first human cryopreservation in China (The first in Asia)

Our cryomedicine team has won the 25th invention patent

Release Time:

2022-09-20 14:34


Recently, the Cold Medicine Center of Shandong Yinfeng Institute of Life Sciences (the research unit of our foundation) won the invention patent of “a kind of placental tissue matrix material and its preparation method” again. So far, the total number of patents granted by the National Intellectual Property Office has reached 25. 


The patent was duly filed on November 25, 2019 and lasted for two years until the patent certificate was granted. Patent discloses a placental tissue matrix material, which is a special scaffold material containing active cytokine receptor prepared from placental tissue, which can actively attract the active ingredient in living body into the material, accumulate the active ingredients of cells, and support cell attachment, infiltration, growth, proliferation and differentiation. 
The repair and reconstruction of tissues and organs has always been a hotspot in the field of tissue engineering, biology and medicine. With the development of technology, tissue engineering products have gradually become an important surgical repair and replacement in clinic, and become the important treatment measures for the absence of tissues and organs and various injuries caused by clinical surgery and accidents. The tissue engineering material is the basis of research and development of this kind of product, and it is expected to be the first choice of surgical repair and replacement in clinical practice. 
At present, most of tissue engineering materials are composed of natural polymer materials which can provide bioactive components, such as collagen, gelatin, hyaluronic acid, chitosan, etc. However, these traditional tissue engineering materials have some disadvantages such as insufficient biomechanical strength, poor integration with body tissue, mismatch between degradation rate and tissue reconstruction. Therefore, using decellularization technology to remove the cells and DNA that cause immune reaction in tissues and obtain extracellular matrix (ECM) as a biological material, the research on tissue engineering is outstanding. 


However, although some products of domestic acellular tissue matrix (ACTM) materials have entered pre-clinical tests, their origins are mostly from animal collagens such as pigs and cattle, which are not only expensive and limited in clinical use, but also have the potential risk of infection and immunorejection. Due to the diversified surgical and clinical requirements, various kinds of tissue engineering products with different specifications, different scales and various requirements for structure and activity are needed, and conventional extracellular matrix and scaffolds are difficult to meet. 
Therefore, Yinfeng Cold Center invented a medical biological material-placental tissue matrix material prepared from human placenta tissue. The placental tissue matrix material of the present invention does not contain immune antigens of allogeneic tissues, retains receptors for various active factors in the extracellular matrix of the placenta tissue, and is various in morphology (e.g., particles, gels and porous scaffolds). The placental tissue matrix material of the present invention can be implanted into tissue defects and wounds in vivo, which facilitates accumulation of active components of cells, supports cell migration, attachment, proliferation and differentiation, accelerates repair of damaged tissues, and can meet the clinical needs of different parts and shapes. 
Yinfeng Cold Medical Center will promote whipping, accelerate technological innovation, promote the transformation of achievements, promote the acellular matrix obtained by the invention to be applied to burn plastic surgery, medical beauty, diabetic foot and other fields as soon as possible, and become an important surgical repair and substitute for clinical treatment, serving human health. 

Share To:

Send MessageClose